<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727647</url>
  </required_header>
  <id_info>
    <org_study_id>3125056</org_study_id>
    <nct_id>NCT02727647</nct_id>
  </id_info>
  <brief_title>Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients</brief_title>
  <official_title>Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title: Comparison of different prophylaxis regimens for hemophilia A pediatric patients
      Principal Investigator: Assistant Professor Darintr Sosothikul, MD Research Question: Does
      different factor VIII dosage effect outcome of hemophilia treatment in term of breakthrough
      bleeding, number of hospital stay and day-off from school? Type Research: Clinical research

      Study design: Single center clinical trials

      Concise methodology:

        1. Study Population: Children with hemophilia A who received treatment at KCMH from May
           2015 to March 2016 will be enrolled in this study. The consent will be obtained before
           the study.

        2. Observation and measurement:

             1. History, interesting clinical data and laboratory data will be recorded in Clinical
                record Form (CRF)

             2. Measurement:

           i. Complete blood count (CBC), Factor VIII level, Factor VIII inhibitor level ii. Number
           of breakthrough bleedings, number of hospital stay and day-off from school iii. Joint
           score from Hemophilia Joint Health Score 2.1 iv. EQ-5D-5L quality of life assessment
           score

        3. Data analysis: The p-value of less than 0.05 will be considered statistically
           significant. Mann-Whitney test will be used to test correlation of these variables (CBC,
           Factor VIII level, Factor VIII inhibitor level, Number of breakthrough bleedings, number
           of hospital stay, day-off from school, Hemophilia Joint Health Score 2.1, EQ-5D-5L
           quality of life assessment score) Sample size: 16 patients

      Potential impacts:

      The outcomes of different factor VIII concentrate dose between 15-20 U/kg/dose 2 times/week
      and 35-40 U/kg/dose 1 time/week will be revealed. These outcomes include number of
      breakthrough bleeding, number of hospital stay, day-off from school, joint health and quality
      of life. The result of this study will guide further study on optimal dose and duration of
      factor VIII treatment of hemophilia A patients in the future.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized bleeding rate per year</measure>
    <time_frame>10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemophilia joint health score</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of FVIII use</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>10 months</time_frame>
    <description>EQ-5D-5L (Thailand version)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital stays</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of school days loss</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FVIII concentration at 35-40 U/kg/dose 1 time/week for 5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FVIII concentration at 15-20 U/kg/dose 2 time/week for 5 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FVIII</intervention_name>
    <description>FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Hemofil-M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FVIII</intervention_name>
    <description>FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Hemofil-M</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemophilia patients with moderate (factor level 1-3%) or severe (factor level &lt;1%)
             severity

        Exclusion Criteria:

          -  Platelet count less than 100,000 /mm3 or other bleeding tendency

          -  Hemophilia patients who have FVIII inhibitor &gt;0.6 BU (modified Nijmogen method)

          -  Hemophilia patients who have no bleeding symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darintr Sosothikul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Hemato/oncology, Department of Pediatrics, Faculty of medicine,Chulalongkorn U</name>
      <address>
        <city>Bangkok</city>
        <state>Pathumwan</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Darintr Sosothikul</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Moderate hemophilia A</keyword>
  <keyword>Severe hemophilia A</keyword>
  <keyword>Intermediate dose prophylaxis</keyword>
  <keyword>Low dose prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

